Castle Biosciences, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. Castle is a commercial-stage diagnostics company whose revenue primarily comes from dermatologic tests, especially DecisionDx-Melanoma. Financial statements are unaudited.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Net revenue | $26.9 million | $22.8 million | Up 17.7% |
| Gross margin | $19.3 million; 71.7% | $19.8 million; 86.7% | Margin down 15.0 percentage points |
| Operating expenses | $51.4 million | $27.1 million | Up 89.6% |
| Operating loss | $24.5 million | $4.3 million | Loss increased |
| Net loss | $24.6 million; $0.97 per share | $4.3 million; $0.17 per share | Loss increased |
| Cash used in operating activities | $21.4 million | $3.6 million | Use increased $17.8 million |
At March 31, 2022, cash and cash equivalents were $309.0 million, down from $329.6 million at year-end 2021; total assets were $444.4 million and stockholders’ equity was $397.3 million. The company reported no outstanding bank debt; its $25 million term loan was repaid in December 2020. Liabilities included $20.8 million of contingent consideration and operating lease obligations.
Material changes and operating trends
- Dermatologic revenue rose $3.4 million to $24.3 million; other revenue increased $0.6 million to $2.5 million. Management attributed growth mainly to higher test volume, easing pandemic restrictions and the expanded sales force.
- Dermatologic test reports increased 68.9% year over year. Total reports across listed product lines were 8,627 in Q1 2022, including 6,023 DecisionDx-Melanoma reports.
- Gross margin percentage declined from 86.7% to 71.7%, reflecting acquired-intangible amortization, laboratory staffing investment and lower favorable revenue adjustments for prior-period tests.
- Research and development expense rose 82.1% to $10.8 million; selling, general and administrative expense rose 67.7% to $30.5 million. Stock-based compensation increased to $8.4 million from $4.9 million.
- Positive revenue adjustments for prior-period tests were $0.6 million, versus $5.3 million in Q1 2021. Management said the prior-year amount included favorable settlements and collections that did not recur.
Outlook, risks and unusual items
- Management said existing cash and expected product-sale cash generation should fund operations for at least the next 12 months. It expects expenses to rise with commercialization, research and development, staffing and public-company costs; near-term gross margin percentage is expected to decline as laboratory capacity is built.
- On April 26, 2022, after quarter-end, Castle completed its AltheaDx acquisition for $65.0 million of initial consideration—approximately $32.5 million cash and $32.5 million in Castle shares—with up to $75.0 million of additional milestone consideration. The filing describes potential integration, dilution and cash-use risks.
- The Cernostics acquisition earnout is up to $50.0 million, based on 2022 commercial milestones. Its fair-value liability rose from $18.3 million to $20.8 million, producing $2.6 million of non-cash expense in Q1.
- Revenue and collections depend substantially on third-party reimbursement: Medicare and Medicare Advantage together represented 86% of Q1 revenue. Revenue estimates are subject to variable consideration, and results may not track test-report volume.
- Castle has not recognized revenue for 2,698 disputed DecisionDx-Melanoma claims denied by an administrative hearing office in 2020; its appeal remained unresolved. Changes to coverage or reimbursement, including pending coverage matters for certain tests, could affect results.
- COVID-19 may continue to affect patient visits, biopsies and test volumes. The filing also cites inflationary personnel costs, regulatory uncertainty for laboratory-developed tests, supplier and laboratory continuity risks, and the possibility that additional financing may be needed; no external funding source is committed.
- Management reported no litigation expected to have a material adverse effect, and stated disclosure controls were effective as of March 31, 2022.
Important facts for investors to verify
- Whether test-volume growth converts into sustainable revenue and collections, given reimbursement uncertainty and the year-over-year decline in favorable prior-period revenue adjustments.
- Current Medicare and commercial coverage, reimbursement rates and outcomes of the DecisionDx-Melanoma claims appeal and other coverage reviews.
- Cash use and liquidity after the AltheaDx cash payment, future acquisition milestones, laboratory expansion and lease commitments.
- Progress and commercial adoption of TissueCypher and IDgenetix, and the costs and results of integrating recent acquisitions.
- Whether operating expense growth, stock-based compensation and margin pressure moderate as revenue scales.